Page last updated: 2024-10-27

gabapentin and Restless Leg Syndrome

gabapentin has been researched along with Restless Leg Syndrome in 65 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

Excerpt	Relevance	Reference
"To compare the efficacy of gabapentin and levodopa-c (Levodopa/Carbidopa) in reducing restless leg syndrome (RLS) symptoms and sleep problems in hemodialysis patients with RLS in a four-week randomized clinical trial."	9.20	Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial. ( Afshari, D; Azimi, H; Ghadami, MR; Heidarnejadian, J; Razazian, N, 2015)
"To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)."	9.10	Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002)
"Dopaminergic agents such as ropinirole are the drugs of first choice in treating restless legs syndrome (RLS)."	9.10	Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. ( Happe, S; Klösch, G; Saletu, B; Sauter, C; Zeitlhofer, J, 2003)
"Nine patients with idiopathic restless legs syndrome (RLS) were treated with 300 mg of gabapentin as an initial dose and an up-titration until relief of symptoms for 4 weeks."	9.09	Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. ( Happe, S; Klösch, G; Saletu, B; Zeitlhofer, J, 2001)
"Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated."	9.08	Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998)
"To synthesize evidence from available randomized controlled trials (RCT) to compare the efficacies of dopaminergic drugs (pramipexole, ropinirole and rotigotine) and α-2-δ ligands (gabapentin enacarbil and pregabalin) for the treatment of restless legs syndrome (RLS)."	8.95	Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. ( Alghothani, L; Iftikhar, IH; Trotti, LM, 2017)
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)."	8.90	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)
"The objective of this study is to assess adherence and persistence of ropinirole, pramipexole, and gabapentin; to investigate factors associated with non-adherence and non-persistence in restless legs syndrome (RLS) patients."	7.88	Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome. ( Hartzema, AG; Kim, J, 2018)
"To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD."	7.81	Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015)
"The aim of the present placebo-controlled sleep laboratory study was to compare the acute effects of gabapentin (GBT) and ropinirole (ROP) in restless legs syndrome (RLS)."	7.76	Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. ( Anderer, P; Gruber, G; Nia, S; Parapatics, S; Saletu, B; Saletu, M; Saletu-Zyhlarz, GM, 2010)
"Gabapentin is an anticonvulsant shown to alleviate symptoms of RLS in two small studies of nonhemodialysis patients."	6.70	A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. ( Bagby, SP; Morris, CD; Thorp, ML, 2001)
"Gabapentin is a well tolerated anticonvulsant, structurally related to gamma-aminobutyric acid, with an unknown mechanism of action."	6.68	Treatment of restless legs syndrome with gabapentin. ( Adler, CH, 1997)
"This study aimed to compare the effect of valerian and gabapentin on restless legs syndrome (RLS) and sleep quality in HD patients."	5.69	Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial. ( Hajizadeh, I; Jamshidi, M; Kargar, H; Kazemi, M; Sadeghi, T, 2023)
"There are several well-known treatments for Restless Legs Syndrome (RLS), including dopamine agonists (pramipexole, ropinirole, rotigotine), anticonvulsants (gabapentin and its analogs, pregabalin), oral or intravenous iron, opioids and benzodiazepines."	5.41	A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use. ( DelRosso, LM; Spruyt, K; Walters, AS; Yeh, PG, 2023)
"To compare the efficacy of gabapentin and levodopa-c (Levodopa/Carbidopa) in reducing restless leg syndrome (RLS) symptoms and sleep problems in hemodialysis patients with RLS in a four-week randomized clinical trial."	5.20	Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial. ( Afshari, D; Azimi, H; Ghadami, MR; Heidarnejadian, J; Razazian, N, 2015)
"Dopaminergic agents such as ropinirole are the drugs of first choice in treating restless legs syndrome (RLS)."	5.10	Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. ( Happe, S; Klösch, G; Saletu, B; Sauter, C; Zeitlhofer, J, 2003)
"To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)."	5.10	Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002)
"Nine patients with idiopathic restless legs syndrome (RLS) were treated with 300 mg of gabapentin as an initial dose and an up-titration until relief of symptoms for 4 weeks."	5.09	Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. ( Happe, S; Klösch, G; Saletu, B; Zeitlhofer, J, 2001)
"Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated."	5.08	Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998)
"To synthesize evidence from available randomized controlled trials (RCT) to compare the efficacies of dopaminergic drugs (pramipexole, ropinirole and rotigotine) and α-2-δ ligands (gabapentin enacarbil and pregabalin) for the treatment of restless legs syndrome (RLS)."	4.95	Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. ( Alghothani, L; Iftikhar, IH; Trotti, LM, 2017)
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)."	4.90	Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014)
") and restless legs syndrome treated with ropinirole and gabapentin, will be discussed."	4.89	Recent advances in sleep research. ( Anderer, P; Saletu, B; Saletu-Zyhlarz, GM, 2013)
"Based on few double-blind, randomized, controlled trials, it seems that the best options to treat restless legs syndrome patients are gabapentin and L-dopa associated to its sustained release formulation."	4.83	Treatment of restless legs syndrome. ( Allis, JC; Pondé, MP; Spolador, T, 2006)
"We present a totally blind adolescent with refractory insomnia due to a combination of Non-24 hour sleep-wake disorder and restless leg syndrome that was successfully treated with tasimelteon, iron replacement, and gabapentin."	3.91	Refractory Insomnia in an Adolescent with Total Blindness. ( Combs, D; Grandner, MA; Tubbs, AS, 2019)
"The objective of this study is to assess adherence and persistence of ropinirole, pramipexole, and gabapentin; to investigate factors associated with non-adherence and non-persistence in restless legs syndrome (RLS) patients."	3.88	Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome. ( Hartzema, AG; Kim, J, 2018)
"To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD."	3.81	Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015)
"The aim of the present placebo-controlled sleep laboratory study was to compare the acute effects of gabapentin (GBT) and ropinirole (ROP) in restless legs syndrome (RLS)."	3.76	Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. ( Anderer, P; Gruber, G; Nia, S; Parapatics, S; Saletu, B; Saletu, M; Saletu-Zyhlarz, GM, 2010)
"Gabapentin is an antiepileptic medication that also has been used for restless legs syndrome."	3.73	Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. ( Lavoie, S; Lipson, J; Zimmerman, D, 2005)
"Restless leg syndrome (Restless legs syndrome, RLS) is a common neurological disorder."	2.82	Exploration of restless legs syndrome under the new concept: A review. ( Guan, R; Liu, Z; Pan, L, 2022)
" Using plasma gabapentin concentration data obtained after administration of GEn in 12 phase 1 to 3 GEn studies in healthy adults or patients with RLS (dose range, 300-2400 mg/d), a population pharmacokinetic (PK) model was developed by nonlinear mixed-effect modeling using NONMEM."	2.78	Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. ( Cundy, KC; Lal, R; Lassauzet, ML; Luo, W; Sukbuntherng, J; Tovera, J, 2013)
"Gabapentin is an anticonvulsant shown to alleviate symptoms of RLS in two small studies of nonhemodialysis patients."	2.70	A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. ( Bagby, SP; Morris, CD; Thorp, ML, 2001)
"Gabapentin is a well tolerated anticonvulsant, structurally related to gamma-aminobutyric acid, with an unknown mechanism of action."	2.68	Treatment of restless legs syndrome with gabapentin. ( Adler, CH, 1997)
"Mycophenolic acid was detected in all cats."	2.61	( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Newer clinical guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control."	2.58	Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease. ( Faulkner, MA, 2018)
"RLS in end-stage renal disease (ESRD) patients is especially problematic due to premature discontinuation of dialysis and increased mortality."	2.55	Clinical management of restless legs syndrome in end-stage renal disease patients. ( Jo, J; Mousa, SA; Sahli, ZT; Tarazi, FI, 2017)
"Idiopathic restless legs syndrome (RLS) can severely affect quality of life and disturb sleep, so that pharmacological treatment is necessary, especially for elderly patients."	2.52	Restless legs syndrome-current therapies and management of augmentation. ( Inoue, Y; Paulus, W; Trenkwalder, C; Winkelmann, J, 2015)
"Treatment of restless legs syndrome (RLS) has as its goals alleviation of the primary symptoms of the disorder and establishment of normal sleep."	2.44	Restless legs syndrome: nonpharmacologic and pharmacologic treatments. ( Allen, RP; Hening, W; Tenzer, P; Winkelman, JW, 2007)
" Challenges with applying TDM in new indications such as RLS include different dosage regimens and consequently different interpretation of serum concentrations."	1.51	Therapeutic drug monitoring of gabapentin in various indications. ( Johannessen Landmark, C; Johannessen, SI; Kinge, E; Larsen Burns, M; Stokke Opdal, M, 2019)
" It may be related with using a similar dosage of dopaminergic drugs."	1.42	Augmentation in restless legs syndrome patients in Korea. ( Cho, YW; Jeon, JY; Lee, HB; Moon, HJ; Song, ML, 2015)
"We report a patient affected by restless legs syndrome as the presenting symptom of multiple myeloma, a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow and monoclonal immunoglobulin in the blood and/or urine."	1.39	Restless legs syndrome as the presenting symptom of multiple myeloma. ( Aricò, D; Ferri, R; Raggi, A; Siragusa, M; Zucconi, M, 2013)
"Restless legs syndrome is divided into primary and secondary forms."	1.35	Restless legs syndrome. ( Killick, R; Wong, K; Yee, B, 2009)

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (9.23)	18.2507
2000's	18 (27.69)	29.6817
2010's	34 (52.31)	24.3611
2020's	7 (10.77)	2.80

Authors

Authors	Studies
Chen, JJ	1
Lee, TH	1
Tu, YK	1
Kuo, G	1
Yang, HY	1
Yen, CL	1
Fan, PC	1
Chang, CH	1
Costales, B	1
Vouri, SM	1
Brown, JD	1
Setlow, B	1
Goodin, AJ	1
Winkelman, JW	3
Liu, Z	1
Guan, R	1
Pan, L	1
Yeh, PG	1
Spruyt, K	1
DelRosso, LM	2
Walters, AS	1
Safarpour, Y	1
Vaziri, ND	1
Jabbari, B	1
Hajizadeh, I	1
Jamshidi, M	1
Kazemi, M	1
Kargar, H	1
Sadeghi, T	1
Bobenko, AI	1
Heller, S	1
Schmitt, N	1
Cherdtrakulkiat, R	1
Lawung, R	1
Nabu, S	1
Tantimavanich, S	1
Sinthupoom, N	1
Prachayasittikul, S	1
Prachayasittikul, V	1
Zhang, B	1
Wu, C	1
Zhang, Z	2
Yan, K	1
Li, C	2
Li, Y	4
Li, L	3
Zheng, C	1
Xiao, Y	1
He, D	1
Zhao, F	1
Su, JF	1
Lun, SM	1
Hou, YJ	1
Duan, LJ	1
Wang, NC	1
Shen, FF	1
Zhang, YW	1
Gao, ZW	1
Li, J	5
Du, XJ	1
Zhou, FY	1
Yin, Z	1
Zhu, J	2
Yan, D	1
Lou, H	1
Yu, H	1
Feng, C	1
Wang, Z	1
Wang, Y	4
Hu, X	1
Li, Z	2
Shen, Y	1
Hu, D	1
Chen, H	1
Wu, X	1
Duan, Y	1
Zhi, D	1
Zou, M	2
Zhao, Z	1
Zhang, X	2
Yang, X	2
Zhang, J	2
Wang, H	1
Popović, KJ	1
Popović, DJ	1
Miljković, D	1
Lalošević, D	1
Čapo, I	1
Popović, JK	1
Liu, M	1
Song, H	2
Xing, Z	1
Lu, G	1
Chen, D	1
Valentini, AM	1
Di Pinto, F	1
Coletta, S	1
Guerra, V	1
Armentano, R	1
Caruso, ML	1
Gong, J	1
Wang, N	1
Bian, L	1
Wang, M	1
Ye, M	1
Wen, N	1
Fu, M	1
Fan, W	1
Meng, Y	1
Dong, G	1
Lin, XH	1
Liu, HH	1
Gao, DM	1
Cui, JF	1
Ren, ZG	1
Chen, RX	1
Önal, B	1
Özen, D	1
Demir, B	1
Akkan, AG	1
Özyazgan, S	1
Payette, G	1
Geoffroy, V	1
Martineau, C	1
Villemur, R	1
Jameel, T	1
Baig, M	1
Gazzaz, ZJ	1
Tashkandi, JM	1
Al Alhareth, NS	1
Khan, SA	1
Butt, NS	1
Wang, J	2
Geng, Y	1
Zhang, Y	3
Wang, X	2
Liu, J	2
Basit, A	1
Miao, T	1
Liu, W	1
Jiang, W	1
Yu, ZY	1
Wu, L	2
Qu, B	1
Sun, JX	1
Cai, AL	1
Xie, LM	1
Groeneveld, J	1
Ho, SL	1
Mackensen, A	1
Mohtadi, M	1
Laepple, T	1
Genovesi, S	1
Nava, E	1
Bartolucci, C	1
Severi, S	1
Vincenti, A	1
Contaldo, G	1
Bigatti, G	1
Ciurlino, D	1
Bertoli, SV	1
Slovak, JE	1
Hwang, JK	1
Rivera, SM	1
Villarino, NF	1
Li, S	1
Cao, G	1
Ling, M	1
Ji, J	1
Zhao, D	1
Sha, Y	1
Gao, X	1
Liang, C	2
Guo, Q	1
Zhou, C	1
Ma, Z	1
Xu, J	1
Wang, C	1
Zhao, W	1
Xia, X	1
Jiang, Y	1
Peng, J	1
Jia, Z	1
Li, F	1
Chen, X	2
Mo, J	1
Zhang, S	2
Li, X	1
Huang, T	1
Zhu, Q	1
Wang, S	1
Ge, RS	1
Fortunato, G	1
Lin, J	2
Agarwal, PK	1
Kohen, A	1
Singh, P	1
Cheatum, CM	1
Zhu, D	1
Hayman, A	1
Kebede, B	1
Stewart, I	1
Chen, G	1
Frew, R	1
Guo, X	1
Gong, Q	1
Borowiec, J	1
Han, S	1
Zhang, M	1
Willis, M	1
Kreouzis, T	1
Yu, K	1
Chirvony, VS	1
Sekerbayev, KS	1
Pérez-Del-Rey, D	1
Martínez-Pastor, JP	1
Palazon, F	1
Boix, PP	1
Taurbayev, TI	1
Sessolo, M	1
Bolink, HJ	1
Lu, M	1
Lan, Y	1
Xiao, J	1
Song, M	1
Chen, C	1
Huang, Q	1
Cao, Y	1
Ho, CT	1
Qi, B	1
Wang, Q	1
Zhang, W	1
Fang, L	1
Xie, CL	1
Chen, R	1
Yang, S	1
Xia, JM	1
Zhang, GY	1
Chen, CH	1
Yang, XW	1
Domenech-Ximenos, B	1
Garza, MS	1
Prat-González, S	1
Sepúlveda-Martínez, Á	1
Crispi, F	1
Perea, RJ	1
Garcia-Alvarez, A	1
Sitges, M	1
Kalumpha, M	1
Guyo, U	1
Zinyama, NP	1
Vakira, FM	1
Nyamunda, BC	1
Varga, M	1
Drácz, L	1
Kolbenheyer, E	1
Varga, F	1
Patai, ÁV	1
Solymosi, N	1
Patai, Á	1
Kiss, J	1
Gaál, V	1
Nyul, Z	1
Mosdósi, B	1
Valdez, M	1
Moosavi, L	1
Heidari, A	1
Novakovic-Agopian, T	1
Kornblith, E	1
Abrams, G	1
McQuaid, JR	1
Posecion, L	1
Burciaga, J	1
D'Esposito, M	1
Chen, AJW	1
Samy El Gendy, NM	1
Wesolowska, P	1
Georg, D	1
Lechner, W	1
Kazantsev, P	1
Bokulic, T	1
Tedgren, AC	1
Adolfsson, E	1
Campos, AM	1
Alves, VGL	1
Suming, L	1
Hao, W	1
Ekendahl, D	1
Koniarova, I	1
Bulski, W	1
Chelminski, K	1
Samper, JLA	1
Vinatha, SP	1
Rakshit, S	1
Siri, S	1
Tomsejm, M	1
Tenhunen, M	1
Povall, J	1
Kry, SF	1
Followill, DS	1
Thwaites, DI	1
Izewska, J	1
Kang, JH	1
Yoon, Y	1
Song, J	1
Van de Winckel, A	1
Gauthier, L	1
Chao, CT	1
Lee, YH	1
Li, CM	1
Han, DS	1
Huang, JW	1
Huang, KC	1
Ni, L	1
Güttinger, R	1
Triana, CA	1
Spingler, B	1
Baldridge, KK	1
Patzke, GR	1
Shen, X	1
Wang, B	1
Xie, S	1
Deng, W	1
Wu, D	1
Zhang, Q	1
Voskamp, BJ	1
Peelen, MJCS	1
Ravelli, ACJ	1
van der Lee, R	1
Mol, BWJ	1
Pajkrt, E	1
Ganzevoort, W	1
Kazemier, BM	1
Tibrewala, R	1
Bahroos, E	1
Mehrabian, H	1
Foreman, SC	1
Link, TM	1
Pedoia, V	1
Majumdar, S	1
Jablonski, CL	1
Leonard, C	1
Salo, P	1
Krawetz, RJ	1
Yoon, N	1
Hong, SN	1
Cho, JG	1
Jeong, HK	1
Lee, KH	1
Park, HW	1
Barman, S	1
Konai, MM	1
Samaddar, S	1
Haldar, J	1
Mohamed, HSH	1
Li, CF	1
Hu, ZY	1
Deng, Z	1
Chen, LH	1
Su, BL	1
Chu, K	1
Liu, YP	1
Li, YB	1
Zhang, H	1
Xu, C	1
Zou, Z	1
Wu, Z	1
Xia, Y	1
Zhao, P	1
Wang, HT	1
de Biase, S	2
Pellitteri, G	1
Gigli, GL	2
Valente, M	2
Hsu, CH	1
Yu, SM	1
Lau, SC	1
Chen, YL	1
Pei, D	1
Liu, IC	1
Iftikhar, IH	1
Alghothani, L	1
Trotti, LM	1
Hamdaoui, M	1
Ruppert, E	1
Comtet, H	1
Kilic-Huck, U	1
Wolff, V	1
Bataillard, M	1
Bourgin, P	1
Raissi, GR	1
Forogh, B	1
Ahadi, T	1
Ghahramanpoori, S	1
Ghaboussi, P	1
Sajadi, S	1
Yepes, G	1
Guitart, X	1
Rea, W	1
Newman, AH	1
Allen, RP	3
Earley, CJ	3
Quiroz, C	1
Ferré, S	1
Faulkner, MA	1
Sinclair, PM	1
Kim, J	1
Hartzema, AG	1
Wang, A	1
Foster, K	1
Skeba, P	1
Hiranniramol, K	1
Larsen Burns, M	1
Kinge, E	1
Stokke Opdal, M	1
Johannessen, SI	1
Johannessen Landmark, C	1
Tubbs, AS	1
Grandner, MA	1
Combs, D	1
Jackson, CV	1
Ferri, R	3
Nagandla, K	1
De, S	1
Aricò, D	1
Raggi, A	1
Siragusa, M	1
Zucconi, M	1
Gagnon, A	1
Clair, AG	1
Amos, LB	1
Grekowicz, ML	1
Kuhn, EM	1
Olstad, JD	1
Collins, MM	1
Norins, NA	1
D'Andrea, LA	1
Saletu, B	4
Anderer, P	2
Saletu-Zyhlarz, GM	2
Kumar, V	1
Ambekar, N	1
Singh, A	1
Venkatasubramanian, G	1
Jeon, JY	1
Moon, HJ	1
Song, ML	1
Lee, HB	1
Cho, YW	1
Guttuso, T	1
Shaman, M	1
Thornburg, LL	1
Cheikh Hassan, HI	1
Brennan, F	1
Collett, G	1
Josland, EA	1
Brown, MA	1
Razazian, N	1
Azimi, H	1
Heidarnejadian, J	1
Afshari, D	1
Ghadami, MR	1
Wijemanne, S	1
Jankovic, J	1
Trenkwalder, C	1
Winkelmann, J	1
Inoue, Y	1
Paulus, W	1
Bruni, O	1
Angriman, M	1
Luchetti, A	1
Güler, S	1
Yavuz, S	1
Nakuş, E	1
Doğru, Y	1
Sahli, ZT	1
Jo, J	1
Mousa, SA	1
Tarazi, FI	1
Gopaluni, S	1
Sherif, M	1
Ahmadouk, NA	1
Conti, CF	1
Oliveira, MM	1
Valbuza, JS	1
Prado, LB	1
Carvalho, LB	1
Prado, GF	1
Biselx, S	1
Büla, C	1
Ghika, J	1
Kushida, CA	1
Becker, PM	1
Ellenbogen, AL	1
Canafax, DM	1
Barrett, RW	1
Yee, B	1
Killick, R	1
Wong, K	1
Konno, M	1
Uchiyama, M	1
Saletu, M	1
Parapatics, S	1
Gruber, G	1
Nia, S	1
Merlino, G	1
Lorenzut, S	1
Lal, R	1
Sukbuntherng, J	1
Luo, W	1
Tovera, J	1
Lassauzet, ML	1
Cundy, KC	1
Garcia-Borreguero, D	1
Larrosa, O	1
de la Llave, Y	1
Verger, K	1
Masramon, X	1
Hernandez, G	1
Burchell, BJ	1
Happe, S	3
Sauter, C	1
Klösch, G	2
Zeitlhofer, J	2
Freye, E	1
Levy, JV	1
Partecke, L	1
Clavadetscher, SC	1
Gugger, M	1
Bassetti, CL	1
Micozkadioglu, H	1
Ozdemir, FN	1
Kut, A	1
Sezer, S	1
Saatci, U	1
Haberal, M	1
Lipson, J	1
Lavoie, S	1
Zimmerman, D	1
Molnar, MZ	1
Novak, M	1
Mucsi, I	1
Spolador, T	1
Allis, JC	1
Pondé, MP	1
Lanz, M	1
Tenzer, P	1
Hening, W	1
Cochran, JW	1
Williams, LB	1
Mellick, GA	1
Mellick, LB	1
Williams, DC	1
Adler, CH	1
Merren, MD	1
Magnus, L	1
Thorp, ML	1
Morris, CD	1
Bagby, SP	1

Clinical Trials (4)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Heart Rate Variability Assessment in Dialysis Patients by Acupuncture[NCT04356794]		61 participants (Actual)	Interventional	2019-08-23	Completed
The Treatment of Sleep Bruxism With the Luco Hybrid OSA Appliance[NCT02882880]		51 participants (Actual)	Interventional	2015-07-31	Completed
"Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"[NCT03330119]	Phase 3	1,494 participants (Actual)	Interventional	2017-10-04	Terminated (stopped due to Lack of Funding/ Resident in charge graduated)
Acute Effects of Gabapentin on Polysomnography Parameters and on Hypothalamic-pituitary-adrenal, Hypothalamic-pituitary-gonadal and Somatotropic Axes During Sleep in Older Men: a Randomized, Double-blind, Placebo-controlled Trial[NCT02599701]	Phase 4	8 participants (Actual)	Interventional	2015-09-30	Terminated (stopped due to Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Narcotic Utilization

"total narcotic utilization measured with Morphine Milligram Equivalent (MME)~The conversion scale being used will be the Center for Disease Control and Prevention Morphine Equivalent Score.~Lower scores represent less opioid use and a better outcome. Higher scores represent more opioid use and a worse outcome." (NCT03330119)
Timeframe: From time of consent until hospital discharge (3 days)

Intervention	MME (Mean)
Alternate Management	33.3
Control	47.2

Reviews

27 reviews available for gabapentin and Restless Leg Syndrome

Article	Year
Pharmacological and non-pharmacological treatments for restless legs syndrome in end-stage kidney disease: a systematic review and component network meta-analysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022, 09-22, Volume: 37, Issue:10 Topics: Adult; Dialysis Solutions; Gabapentin; Humans; Kidney Failure, Chronic; Network Meta-Analysis; Renal	2022
Treating Severe Refractory and Augmented Restless Legs Syndrome. Chest, 2022, Volume: 162, Issue:3 Topics: Adult; Analgesics, Opioid; Dopamine Agonists; Female; Gabapentin; Humans; Quality of Life; Restless	2022
Exploration of restless legs syndrome under the new concept: A review. Medicine, 2022, Dec-16, Volume: 101, Issue:50 Topics: Dopamine Agonists; Gabapentin; Humans; Iron; Quality of Life; Restless Legs Syndrome	2022
A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use. Tremor and other hyperkinetic movements (New York, N.Y.), 2023, Volume: 13 Topics: Anticonvulsants; Carbamazepine; Gabapentin; Glutamates; Humans; Restless Legs Syndrome	2023
Restless Legs Syndrome in Chronic Kidney Disease- a Systematic Review. Tremor and other hyperkinetic movements (New York, N.Y.), 2023, Volume: 13 Topics: Child; Dopamine Agents; Gabapentin; Humans; Iron; Pregabalin; Quality of Life; Renal Insufficiency,	2023
Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227 Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P	2019
Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. European journal of neurology, 2017, Volume: 24, Issue:12 Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dopamine Agonists; Gabapentin; gamma-Aminobuty	2017
Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease. CNS drugs, 2018, Volume: 32, Issue:2 Topics: Animals; Anticonvulsants; Calcium Channels; Carbamates; Gabapentin; gamma-Aminobutyric Acid; Humans;	2018
Interventions for chronic kidney disease-associated restless legs syndrome. International journal of evidence-based healthcare, 2018, Volume: 16, Issue:3 Topics: Exercise Therapy; Gabapentin; Humans; Indoles; Iron-Dextran Complex; Levodopa; Randomized Controlled	2018
Restless legs syndrome: pathophysiology and modern management. Postgraduate medical journal, 2013, Volume: 89, Issue:1053 Topics: Amines; Anemia; Anticonvulsants; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Dopamine Agon	2013
Sensory symptoms in restless legs syndrome: the enigma of pain. Sleep medicine, 2013, Volume: 14, Issue:10 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Recent advances in sleep research. Psychiatria Danubina, 2013, Volume: 25, Issue:4 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Amines; Antiparkinson Agents; Biomedical Research;	2013
Latest guidelines and advances for treatment of restless legs syndrome. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:4 Topics: Amines; Analgesics, Opioid; Carbamates; Cyclohexanecarboxylic Acids; Dopamine Agonists; Gabapentin;	2014
Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. European journal of obstetrics, gynecology, and reproductive biology, 2014, Volume: 181 Topics: Amines; Anticonvulsants; Birth Weight; Congenital Abnormalities; Cyclohexanecarboxylic Acids; Female	2014
Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep medicine, 2015, Volume: 16, Issue:6 Topics: Amines; Analgesics, Opioid; Benzothiazoles; Cyclohexanecarboxylic Acids; Dopamine Agonists; Gabapent	2015
Restless legs syndrome-current therapies and management of augmentation. Nature reviews. Neurology, 2015, Volume: 11, Issue:8 Topics: Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Dopamine Agonists; Drug Sy	2015
Clinical management of restless legs syndrome in end-stage renal disease patients. CNS spectrums, 2017, Volume: 22, Issue:1 Topics: Amines; Analgesics, Opioid; Benzodiazepines; Benzothiazoles; Comorbidity; Cyclohexanecarboxylic Acid	2017
Interventions for chronic kidney disease-associated restless legs syndrome. The Cochrane database of systematic reviews, 2016, 11-07, Volume: 11 Topics: Amines; Anticonvulsants; Ascorbic Acid; Cyclohexanecarboxylic Acids; Dopamine Agonists; Exercise The	2016
Anticonvulsants to treat idiopathic restless legs syndrome: systematic review. Arquivos de neuro-psiquiatria, 2008, Volume: 66, Issue:2B Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabape	2008
[Update on the treatment of restless legs syndrome]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:5 Topics: Amines; Analgesics, Opioid; Anticonvulsants; Baths; Benzodiazepines; Cyclohexanecarboxylic Acids; Do	2009
ADMET considerations for restless leg syndrome drug treatments. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:10 Topics: Amines; Anticonvulsants; Benzothiazoles; Carbamates; Cyclohexanecarboxylic Acids; Dopamine Agents; D	2012
Management of restless legs syndrome in patients on dialysis. Drugs, 2006, Volume: 66, Issue:5 Topics: Amines; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic Acids; Dopamine Agents; G	2006
Treatment of restless legs syndrome. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2006, Volume: 28, Issue:4 Topics: Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Dopamine Agents; Double-Bl	2006
[When the legs have to keep moving at night--the restless legs syndrome]. MMW Fortschritte der Medizin, 2007, May-21, Volume: 149 Suppl 2 Topics: Adult; Amines; Analgesics, Opioid; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Dopamine Ago	2007
Restless legs syndrome: nonpharmacologic and pharmacologic treatments. Geriatrics, 2007, Volume: 62, Issue:10 Topics: Amines; Anemia, Iron-Deficiency; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic	2007
Periodic limb movements of sleep and the restless legs syndrome. Virginia medical quarterly : VMQ, 1996,Fall, Volume: 123, Issue:4 Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Folic Acid; Gabapentin; gamma-Aminob	1996
Nonepileptic uses of gabapentin. Epilepsia, 1999, Volume: 40 Suppl 6 Topics: Acetates; Amines; Analgesics; Antimanic Agents; Antiparkinson Agents; Bipolar Disorder; Clinical Tri	1999

Trials

13 trials available for gabapentin and Restless Leg Syndrome

Article	Year
Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2023, Volume: 27, Issue:4 Topics: Gabapentin; gamma-Aminobutyric Acid; Humans; Renal Dialysis; Restless Legs Syndrome; Sleep Quality;	2023
Evaluation of Acupuncture in the Treatment of Restless Legs Syndrome: A Randomized Controlled Trial. Journal of acupuncture and meridian studies, 2017, Volume: 10, Issue:5 Topics: Acupuncture Therapy; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma	2017
Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015, Volume: 26, Issue:2 Topics: Adult; Aged; Amines; Carbidopa; Cyclohexanecarboxylic Acids; Drug Combinations; Gabapentin; gamma-Am	2015
Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology, 2009, Feb-03, Volume: 72, Issue:5 Topics: Adult; Amines; Anti-Anxiety Agents; Carbamates; Central Nervous System; Cyclohexanecarboxylic Acids;	2009
Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. Journal of clinical pharmacology, 2013, Volume: 53, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Carbamates; Cyclohexanecarboxylic Acids; Female;	2013
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology, 2002, Nov-26, Volume: 59, Issue:10 Topics: Acetates; Adult; Aged; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Method;	2002
Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology, 2003, Volume: 48, Issue:2 Topics: Acetates; Adult; Aged; Amines; Calcium Channel Blockers; Cross-Over Studies; Cyclohexanecarboxylic A	2003
Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD)--correlation with neurophysiological parameters--. Neurophysiologie clinique = Clinical neurophysiology, 2004, Volume: 34, Issue:2 Topics: Acetates; Adult; Amines; Anesthesia; Anesthetics, Intravenous; Cyclohexanecarboxylic Acids; Electric	2004
Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Renal failure, 2004, Volume: 26, Issue:4 Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dopamine Agonists; Female; Gabapentin;	2004
Treatment of restless legs syndrome with gabapentin. Clinical neuropharmacology, 1997, Volume: 20, Issue:2 Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amin	1997
Gabapentin for treatment of pain and tremor: a large case series. Southern medical journal, 1998, Volume: 91, Issue:8 Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc	1998
A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 38, Issue:1 Topics: Acetates; Aged; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Bli	2001
Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology, 2001, Nov-13, Volume: 57, Issue:9 Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amin	2001

Other Studies

25 other studies available for gabapentin and Restless Leg Syndrome

Article	Year
Treatment initiation and utilization patterns of pharmacotherapies for early-onset idiopathic restless legs syndrome. Sleep medicine, 2022, Volume: 96 Topics: Adult; Cross-Sectional Studies; Dopamine Agonists; Gabapentin; Humans; Pramipexole; Restless Legs Sy	2022
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2017, Volume: 17, Issue:6 Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B	2017
Restless legs syndrome related to hemorrhage of a thoracic spinal cord cavernoma. The journal of spinal cord medicine, 2018, Volume: 41, Issue:2 Topics: Female; Gabapentin; Hemorrhage; Humans; Magnetic Resonance Imaging; Middle Aged; Polysomnography; Re	2018
Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Annals of neurology, 2017, Volume: 82, Issue:6 Topics: Amines; Animals; Cerebral Cortex; Corpus Striatum; Cyclohexanecarboxylic Acids; Dopamine Agonists; G	2017
Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome. Sleep medicine, 2018, Volume: 44 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Dopamine Agonists; Female; Gabapentin; Huma	2018
Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period. Sleep medicine, 2018, Volume: 52 Topics: Analgesics; Analgesics, Opioid; Dopamine Agonists; Electromyography; Female; Gabapentin; Humans; Ind	2018
Therapeutic drug monitoring of gabapentin in various indications. Acta neurologica Scandinavica, 2019, Volume: 139, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Drug Monitorin	2019
Refractory Insomnia in an Adolescent with Total Blindness. The Yale journal of biology and medicine, 2019, Volume: 92, Issue:2 Topics: Adolescent; Benzofurans; Blindness; Cyclopropanes; Drug Resistance; Drug Therapy, Combination; Femal	2019
A 15-Year-Old Girl With Sleep-Onset Insomnia and Poor Sleep Quality. Chest, 2019, Volume: 156, Issue:1 Topics: Adolescent; Anticonvulsants; Diagnosis, Differential; Female; Gabapentin; Humans; Restless Legs Synd	2019
Restless legs syndrome as the presenting symptom of multiple myeloma. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2013, Apr-15, Volume: 9, Issue:4 Topics: Aged; Amines; Anemia, Iron-Deficiency; Antiparkinson Agents; Benzothiazoles; Cyclohexanecarboxylic A	2013
Treatment of pediatric restless legs syndrome. Clinical pediatrics, 2014, Volume: 53, Issue:4 Topics: Adolescent; Amines; Analgesics; Anticonvulsants; Antioxidants; Benzothiazoles; Child; Child, Prescho	2014
Successful treatment of antipsychotic-induced restless legs syndrome with gabapentin. Asian journal of psychiatry, 2014, Volume: 9 Topics: Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm	2014
Augmentation in restless legs syndrome patients in Korea. Sleep & breathing = Schlaf & Atmung, 2015, Volume: 19, Issue:2 Topics: Aged; Aged, 80 and over; Amines; Benzothiazoles; Cross-Sectional Studies; Cyclohexanecarboxylic Acid	2015
Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. Journal of pain and symptom management, 2015, Volume: 49, Issue:4 Topics: Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-	2015
Leg kicking and rubbing as a highly suggestive sign of pediatric restless legs syndrome. Sleep medicine, 2015, Volume: 16, Issue:12 Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans	2015
[A case of painful legs and moving toes syndrome treated with gabapentin]. Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology, 2016, Volume: 28, Issue:2 Topics: Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Fema	2016
[Restless legs syndrome in the elderly: an unrecognized disorder]. Revue medicale suisse, 2008, Nov-05, Volume: 4, Issue:178 Topics: Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxyli	2008
Restless legs syndrome. Australian family physician, 2009, Volume: 38, Issue:5 Topics: Algorithms; Amines; Analgesics, Opioid; Benzodiazepines; Carbidopa; Causality; Cyclohexanecarboxylic	2009
Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:4 Topics: Amines; Anti-Dyskinesia Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric	2010
Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition. The Johns Hopkins medical letter health after 50, 2011, Volume: 23, Issue:4 Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Drug Approval; Drug Label	2011
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology, 2003, May-13, Volume: 60, Issue:9 Topics: Acetates; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Double-Blind Method; G	2003
Restless legs syndrome: clinical experience with long-term treatment. Sleep medicine, 2004, Volume: 5, Issue:5 Topics: Adult; Aged; Amines; Clonazepam; Cyclohexanecarboxylic Acids; Dopamine Agonists; Drug Therapy, Combi	2004
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:6 Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic A	2005
Restless legs syndrome. JAMA, 1996, Jan-17, Volume: 275, Issue:3 Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	1996
Management of restless legs syndrome with gabapentin (Neurontin) Sleep, 1996, Volume: 19, Issue:3 Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Female; Ga	1996

chemdatabank.com